temozolomide 5mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 5mg
temozolomide 100mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 100mg
temozolomide 140mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 140mg
temozolomide 180mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 180mg
temozolomide 20mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 20mg
temozolomide 250mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 250mg
zoledronic acid 5mg100ml solution for infusion vials
sun pharmaceutical industries europe b.v. - zoledronic acid monohydrate - solution for infusion - 50microgram/1ml
mesalamine capsule, extended release
sun pharmaceutical industries inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine extended-release capsules are indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis. mesalamine extended-release capsules are contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or any components of this medication.
absorica- isotretinoin capsule absorica ld- isotretinoin capsule
sun pharmaceutical industries, inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - isotretinoin 10 mg - absorica and absorica ld are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. because of significant adverse reactions associated with its use, absorica and absorica ld are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. limitations of use : if a second course of absorica/absorica ld therapy is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy [see dosage and administration (2.2)]. absorica/absorica ld is contraindicated in pregnancy [see warnings and precautions (5.1) and use in specific populations (8.1)]. absorica/absorica ld is contraindicated in patients with hypersensitivity to isotretinoin (or vitamin a, given the chemical similarity to isotretinoin) or to any of its components (anaphy
imipramine hydrochloride- imipramine hydrochloride tablet, film coated
sun pharmaceutical industries, inc. - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long